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Abstract
Objective—To determine the impact of hormonal contraceptive methods on risk of HIV 
acquisition among HIV-negative women cohabiting with HIV-positive male partners.
Study design—From 1994–2012, HIV discordant couples recruited from a couples’ voluntary 
HIV counseling and testing center in Lusaka, Zambia were followed longitudinally. HIV-negative 
partners were tested quarterly. This analysis is restricted to couples in which the man was HIV-
positive and the woman was HIV-negative at enrollment and the man was not on antiretroviral 
treatment. Multivariate Cox models evaluated associations between time-varying contraceptive 
methods and HIV acquisition among women. Sensitivity analyses explored exposure 
misclassification and time-varying confounder mediation.
Results—Among 1393 couples, 252 incident infections occurred in women over 2842 couple-
years (8.9 infections per 100 couple-years; 95% CI, 7.8–10.0). Multivariate Cox models indicated 
that neither injectable [adjusted hazard ratio (aHR)=1.2; 95% CI, 0.8–1.7], oral contraceptive pill 
(OCP, aHR=1.3; 95% CI, 0.9–1.8), or implant (aHR=1.1; 95% CI, 0.5–2.2) use was significantly 
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associated with HIV acquisition relative to non-hormonal contraception controlling for woman's 
age, literacy and time-varying measures of genital ulceration/inflammation. This remained true 
when only looking at the subset of infections acquired from the spouse (82% of infections) and 
additionally controlling for baseline HIV viral load of the male partner, pregnancy status, and 
time-varying measures of sperm on a vaginal swab wet prep and self-reported unprotected sex. 
OCP and injectable users reported more unprotected sex (p<.001), and OCP users were more 
likely to have sperm on vaginal swab (p=.1) than nonhormonal method users.
Conclusions—We found no association between hormonal contraception and HIV acquisition 
risk in women. Condom use and reinforced condom counseling should always be recommended 
for HIV discordant couples. HIV testing of sex partners together is critical to establish HIV risk, 
ascertain couple fertility intentions and counsel appropriately.
Implications—These findings add to a controversial literature and uniquely address several 
common design and analytic challenges faced by previous studies. After controlling for 
confounders, we found no association between hormonal contraception and HIV acquisition risk 
in women. We support promoting condoms for HIV prevention and increasing the contraceptive 
method mix to decrease unintended pregnancy.
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1. Introduction
Hormonal contraception (HC), including injectable depot medroxyprogesterone acetate 
(DMPA) and oral contraceptive pills (OCPs), prevents unintended pregnancy [1] and is 
widely used in high HIV prevalence areas [2]. After reviewing the evidence, a 2014 World 
Health Organization meeting recommended that no restrictions (Medical Eligibility Criteria 
Category 1) be placed on HC use by women at risk for HIV and that “women and couples at 
high risk of HIV acquisition considering progestogen-only injectables should also be 
informed about and have access to HIV preventive measures, including male and female 
condoms” [1].
However, extant evidence is conflicting and highly debated [1,3–7]. In a recent systematic 
review, one out of eight studies deemed “informative but with important limitations” found 
OCP use significantly increased HIV acquisition risk in women. In that same review, four 
out of nine studies deemed “informative but with important limitations” found injectable 
contraception significantly increased HIV acquisition risk in women (notably, one found 
increased risk in marginal structural models but not Cox models) [8]. In a meta-analysis of 
observational studies of hormonal contraceptive method use and risk of HIV acquisition 
among women published in 2015, ten of twelve studies that met inclusion criteria indicated 
moderate increased risk of HIV acquisition among women using DMPA; none of the 10 
studies that met inclusion criteria indicated increased risk among women using OCPs [9]. 
Finally, in another meta-analysis also published in 2015, DMPA use was associated with 
HIV acquisition relative to non-hormonal method use after pooling 18 studies, but this 
association became non-significant when looking at studies deemed to be at lower risk for 
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methodological bias [10]. Limited data exist evaluating the association between HIV 
acquisition risk and contraceptive implants [8].
Various analytic design and methodological challenges faced by previous studies have made 
findings difficult to synthesize. As a result, recommendations were recently developed for 
more rigorous and consistent analytic methods [11]. The methodological design of the 
present study allowed for comprehensive consideration of these recommendations. Our 
objective was to determine the impact of HC, including injectable DMPA, OCPs and 
implants, on risk of HIV acquisition among women in HIV discordant couples.
2. Methods
2.1. Participants and ethics
From 1994–2012, married or cohabiting HIV sero-discordant (one partner HIV-1 infected 
and one uninfected) couples living in Lusaka, Zambia were enrolled in a prospective study. 
Discordant couples were identified from couples’ voluntary HIV counseling and testing 
(CVCT) services offered by the Rwanda Zambia HIV Research Group (RZHRG). RZHRG 
CVCT promotions, recruitment [12,13], enrollment, retention [14], testing, counseling 
[14,15] and cohort demographics [16] have been described previously. Briefly, CVCT 
includes group counseling, rapid HIV testing, and joint post-test couple counseling. This 
analysis is restricted to couples in which the man was HIV-positive and the woman was 
HIV-negative (M+F−) at enrollment, the man was not on antiretroviral treatment, and the 
couple had at least one follow-up visit. This study was approved by the Office for Human 
Research Protections-registered Institutional Review Boards at Emory University and in 
Zambia. Written informed consent was obtained from participants.
2.2. Exposure
Contraceptive methods [categorized as no method/condoms alone, combined OCPs 
(progesterone-only typically prescribed to breastfeeding women until children were 6 
months old), DMPA injectables (150 mg IM dosage), copper intrauterine device (IUD), 
contraceptive implant (Norplant, Jadelle), or permanent methods (hysterectomy/tubal 
ligation/vasectomy)] were provided at the research site at baseline and at three-monthly 
follow-up visits. In our primary analysis, contraceptive methods were categorized as 
implant, injectable, or OCP versus non-HC control (which includes couples using no 
method/condoms alone, copper IUD, or who had a hysterectomy/tubal ligation/vasectomy).
2.3. Baseline covariates
At enrollment, baseline demographic data were collected including age, years cohabiting, 
monthly income, and Nyanja literacy (the most commonly used local language in Lusaka). 
Behavioral risk factors included number of previous pregnancies, current pregnancy, fertility 
intentions and number of lifetime sexual partners. Clinical characteristics of HIV-positive 
men partners included viral load (VL) categorized as ≥100,000 copies/mL, ≥10,000 to 
<100,000 copies/mL, or <10,000 copies/mL [17].
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Data collected at scheduled three-monthly follow-up visits included prior three month: 
incident pregnancy, prevalent pregnancy, self-reported number of protected and unprotected 
sex acts, any self-reported sex with the study partner with and without a condom and 
presence of sperm on a vaginal swab wet prep. Composite variables for genital ulceration 
were created from time-varying measures of chronic/recurrent or acute genital or perianal 
ulcers (whether diagnosed/treated at the research clinic or reported by the client); ulceration 
upon physical examination (including erosion or friability of the cervix or vagina in 
women); or newly positive rapid plasma reagin serology for syphilis [18]. Composite 
variables for genital inflammation were created from time-varying measures of genital 
inflammation, genital discharge and trichomoniasis, gonorrhea, chlamydia, candida or 
bacterial vaginosis [19].
2.5. Outcomes
This analysis considers the association between time-varying HC method use and two 
outcomes of interest: (1) any incident HIV infection among women partners and (2) incident 
HIV infection genetically linked to the cohabiting male partner. HIV testing using rapid 
serologic tests was conducted at three-monthly visits [15]. By comparing conserved PCR-
amplified nucleotide sequences from each partner, we determined whether incident 
infections were genetically linked to the study partner or were unlinked (acquired from 
outside the study couple) [20]. Eleven couples with unknown linkage were classified as 
linked [20,21].
2.6. Longitudinal data collection
Data collection varied by type and frequency over 17 years of follow-up. Plasma banking for 
VL testing was available beginning in 1999. From 1994 to 2002, both partners were seen 
quarterly, had physical and genital exams, and received laboratory screening for sexually 
transmitted infections (STIs). Routine p24 antigen screening began in 2003. From 2002 to 
2011, fertility goals were recorded. Physical exams and STI laboratory diagnoses were 
performed at baseline and thereafter given signs and symptoms of STI. In 2007, HIV-
negative women were seen at visit months 0, 1, 2 and 3 and completed a sexual exposure 
risk assessment at quarterly visits. Couples with at least one exposure (unprotected sex, 
sperm or trichomonas on a wet prep, incident pregnancy or incident STI) received monthly 
HIV testing until the next quarterly visit, at which time the risk assessment was repeated. 
From 2008 to 2011, HIV-negative partners were tested monthly.
2.7. Data analysis
Analyses were conducted with SAS v9.3 (Cary, NC, USA). Baseline demographic, 
behavioral and clinical data are described by HIV transmission status using counts and 
percentages (for categorical variables) or means and standard deviations (for continuous 
variables). Index HIV-positive male partner characteristics are only described for genetically 
linked infections.
Infection rates were calculated as the number of incident infections per couple-year of 
follow-up, stratified by contraceptive method type. Hormonal method-specific seroincidence 
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rates were compared to a non-HC reference group using univariate Cox models. Couples 
were censored if either partner died, the couple separated, the positive partner started 
antiretroviral therapy or if either partner was lost to follow-up.
Bivariate associations between covariates and outcomes of interest were evaluated via crude 
hazard ratios (HRs) and 95% confidence intervals (CIs). Multivariate Cox models estimated 
the effect of time-varying contraceptive method type on incident HIV acquisition. Effect-
measure modification was considered for genital ulceration, inflammation, VL of the HIV-
positive partner at baseline, fertility intentions, and woman's age. Covariates significantly 
(p<.05) associated with the exposure and outcome of interest in univariate analyses were 
considered as potential confounders. Multi-collinearity was assessed; if any two variables 
were found to be collinear, the variable with the weakest association with the outcome was 
removed. The proportional hazards assumption was confirmed for time-independent 
covariates.
2.8. Sensitivity analyses
Sensitivity analyses explored the effects of different contraceptive method exposure 
categorizations and control groups, misclassification of unprotected sex, controlling for 
pregnancy, and potential bias due to time-varying confounders simultaneously acting as 
mediators. To address the first issue, we considered all methods disaggregated versus none/
condom control group; cumulative injectable exposure (calculated as the time-varying 
cumulative sum of intervals reporting injectable use) versus non-HC control; and cumulative 
OCP exposure versus non-HC control. To assess misclassification of self-reported 
unprotected sex, we evaluated the association between this measure and sperm on wet prep 
in the past three months, incident pregnancy, HIV acquisition, and genital ulceration/
inflammation using Chi-square tests. Models of incident linked seroconversion were run 
using a composite measure of self-reported unprotected sex (i.e., using an indicator of any 
self-reported unprotected sex, sperm on vaginal swab wet prep, incident pregnancy, or 
incident STI). We estimated our results both controlling and not controlling for pregnancy. 
Marginal structural models estimated through inverse probability weighting were used to 
adjust for time-varying confounders which may simultaneously act as mediators. Finally, we 
conducted our analyses among a subset of couples with no indication of condomless sex 
(using an indicator of any self-reported unprotected sex, sperm on vaginal swab wet prep, 
incident pregnancy, or incident STI) since the last study interval.
2.9. Unprotected sex, contraceptive method use, and pregnancy
We explored differences in contraceptive method use by measures of unprotected sex using 
Chi-square tests for categorical variables and t-tests (unequal variance) for continuous 
variables. We also explored differences in pregnancy status (categorized as pregnant, up to 
six months post-partum, or not pregnant/post-partum) by measures of protected and 
unprotected sex using chi-square tests for categorical variables and t tests (unequal variance) 
for continuous variables.
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3.1. Baseline demographics and bivariate analyses (Tables 1–2)
Eighty-two percent of couples were non-seroconverters (n=1141), 15% acquired genetically 
linked infections (n= 207), and 3% acquired genetically unlinked infections (n=45). Couples 
were followed for a median of 440 days (IQR=756).
Baseline risk factors significantly associated with incident HIV infection included younger 
age of the woman, fewer years cohabiting, illiteracy in Nyanja, fewer previous pregnancies, 
and the woman desiring more children. Additional baseline risk factors significantly 
associated with incident genetically linked HIV infection included younger age of the man, 
pregnancy, the man desiring more children, and higher VL of the man (Table 1).
Time-varying covariates significantly associated with incident genetically linked HIV 
infection included self-reported unprotected sex with the study partner, sperm on a wet prep 
(Table 2). Time-varying measures of genital inflammation or ulceration in either partner in 
the past three months were significantly associated with any incident infection and 
genetically linked infections (data not shown).
3.2. Seroconversion rates by contraceptive method (Table 3)
Of 1393 couples, 252 seroconversions occurred over 2841.9 couple-years (CY) of follow-
up. Women using OCPs or injectables since the previous follow-up visit had higher rates of 
seroconversion relative to women using non-HC methods since the previous follow-up visit; 
these differences were not statistically significant.
3.3. Multivariate analyses (Table 4)
HC use was not associated in multivariate analyses with any incident HIV infection or the 
subset of genetically linked infections. No effect-measure modification by genital ulceration, 
genital inflammation, VL, fertility intentions, or woman's age was observed. Collinear 
variables included: man and woman age, number of prior pregnancies, and years cohabiting 
(woman age retained).
Among all infections, use of implant, injectables, or OCPs was not associated with HIV 
acquisition relative to non-hormonal methods when controlling for woman's age (per year 
increase), literacy in Nyanja, time-varying measures of genital ulceration and inflammation 
in the woman partner in the past three months, and time interval since enrollment.
Among linked infections, use of implant, injectables, or OCPs was not associated with HIV 
acquisition relative to non-hormonal methods controlling for the above factors, baseline 
pregnancy, sperm present on a vaginal swab wet prep, couples’ self-reported unprotected 
sex in the last three months, time-varying measures of genital ulceration and inflammation 
of the man in the past three months, and man's baseline log VL.
3.4. Sensitivity analyses
Analyzing different exposure categorizations, controlling for time-varying pregnancy, 
removing IUD users from the control group, and controlling for fertility intentions did not 
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yield different conclusions. In almost two-thirds of intervals during which incident HIV was 
detected, women reported no unprotected sex in the prior three months. Women reported no 
unprotected sex in almost 40% of intervals during which an incident pregnancy was 
detected. Using a composite measure to indicate unprotected sex did not yield different 
results. Marginal structural models did not yield different results (i.e., marginal structural 
models also did not indicate any association between hormonal contraceptive method use 
and HIV acquisition risk). Finally, performing these analyses among couples with no 
indication of condomless sex did not yield different results, and these non-significant 
findings were of the same magnitude as those for the entire cohort.
3.5. Unprotected sex, contraceptive method use, and pregnancy (Tables 5–6)
OCP users reported a higher number of unprotected sex acts with the study partner in the 
past three months and had sperm on a wet prep more often than nonhormonal method users. 
Injectable users reported more unprotected sex than nonhormonal method users. Implant 
users reported a lower number of unprotected sex acts with the study partner in the past 
three months, reported less unprotected sex, and had sperm on a wet prep less often than 
nonhormonal method users (Table 5).
Pregnant women reported a higher average number of protected sex acts relative to post-
partum women and a higher average number of unprotected sex acts relative to post-partum 
or non-pregnant/non-post-partum women. Pregnant women were more likely to report sex 
without a condom (Table 6).
4. Discussion
Use of oral or injectable HC was not associated with increased risk of HIV acquisition 
among Zambian women in HIV discordant couples after adjustment for behavioral and 
biological risk factors. This investigation, both in design and analysis, overcomes several 
challenges faced by previous studies [11]. We measured various self-reported and biological 
fixed and time-varying measures of unprotected sex over 17 years of prospective follow-up. 
We estimated HIV acquisition risk related to contraceptive implants. Contraception was 
provided at the research site and was measured frequently to capture high rates of stopping 
and switching; in our cohorts, we have observed that about 25% of women switch methods 
during follow-up, with most discontinuation/switching observed among injectable (34%) 
and IUD (33%) users [13,22]. This is one of few studies to differentiate between genetically 
linked versus unlinked infections, important when modeling index partner covariates. 
Discordant couples have relatively little within-sample variation in HIV exposure risk. 
Finally, we corroborated our findings with marginal structural models and rigorous 
sensitivity analyses.
The relationships between measures of unprotected sex and HC use, pregnancy, and post-
partum periods were of particular interest. The reproductive lifetime of most women in 
Africa cycles through these three stages, each of which involves endogenous and/or 
exogenous hormonal influences. We found the high rates of biological and self-reported 
measures of unprotected sex during OCP use, injectable use, and pregnancy surprising. This 
illustrates the complexity of the relationships between behavioral and biological risk factors 
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for HIV transmission and indicates that counseling must emphasize maintaining consistent 
condom use regardless of pregnancy status or other contraceptive method use.
Hormonal implant use was associated with less unprotected sex and fewer pregnancies 
relative to other methods and had a reduced adjusted hazard ratio for seroconversion. 
Further research is warranted to assess the role of this effective and cost-effective 
contraceptive method, along with the copper IUD, in women and couples at risk of HIV. 
Ongoing long-acting reversible contraception (LARC) promotion and provision for those 
wishing to delay pregnancy is important given high rates of unprotected sex and unintended 
pregnancy observed among OCP users – we have previously shown that the rate of 
unintended pregnancy among OCP users in our discordant couple cohorts (20.7/100 CY) 
was not significantly lower than women reporting no method/condom use only [23].
Selection bias due to enrollment and loss to follow-up have been thoroughly explored in our 
cohorts: among M+F-couples, older age and current contraceptive use are predictive of 
enrollment, while residence far from the clinic, younger age, and women's age at first 
intercourse being ≤17 are predictive of attrition [14]. Our findings may therefore be most 
generalizable to relatively older, contraception experienced couples. Additionally, our study 
was underpowered to rule out a type II error in conclusions drawn from the univariate 
associations between seroincidence rates in implant versus non-HC control users.
Based on our findings, we support efforts to increase: 1) the contraceptive method mix to 
decrease unintended pregnancy, in particular access to LARC methods which are not 
currently available to many African women, 2) reinforced condom counseling for all persons 
at risk of HIV, and 3) couple's HIV testing to ascertain the most immediate source of HIV 
risk of negative adults and support couple-level fertility intentions.
Pragmatically, the latter can be achieved by integrating HIV and family planning services 
with a focus on couples. Finally, when weighing the current body of published evidence, the 
effectiveness of HC, especially hormonal LARC methods, to decrease unintended 
pregnancy, maternal and child mortality, and vertical HIV transmission must be considered 
when making policy recommendations.
Acknowledgments
We would like to acknowledge the couples and staff in Zambia that made this study possible.
The corresponding author had full access to all of the data in the study and takes responsibility for the integrity of 
the data and the accuracy of the data analysis.
This study was supported by the National Institutes of Child Health and Development (NICHD RO1 HD40125); 
National Institute of Mental Health (NIMH R01 66,767); the AIDS International Training and Research Program 
Fogarty International Center (D43 TW001042); the Emory Center for AIDS Research (P30 AI050409); National 
Institute of Allergy and Infectious Diseases (NIAID R01 AI51231; NIAID R01 AI040951; NIAID R01 AI023980; 
NIAID R01 AI64060; NIAID R37 AI51231); the US Centers for Disease Control and Prevention 
(5U2GPS000758); and the International AIDS Vaccine Initiative. This study was made possible by the generous 
support of the American people through the United States Agency for International Development (USAID). The 
contents are the responsibility of the International AIDS Vaccine Initiative and do not necessarily reflect the views 
of USAID or the United States Government. The funders had no role in study design, data collection and analysis, 
decision to publish, or preparation of the manuscript.
Wall et al. Page 8














1. World Health Organization. Hormonal contraceptive methods for women at high risk of HIV and 
living with HIV: 2014 Guidance statement. Geneva, Switzerland: 2014. 
2. United Nations Department of Economic and Social Affairs. World Contraceptive Use 2011. 2011
3. Westhoff CL, Winikoff B. DMPA and HIV: do we need a trial? Contraception. 2014; 90(4):353. 
[PubMed: 25183262] 
4. Jones HE. Time to focus on improving the contraceptive method mix in high HIV prevalence 
settings and let go of unanswerable questions. Contraception. 2014; 90(4):357–9. [PubMed: 
24993486] 
5. Colvin, CJ.; Harrison, A. Broadening the debate over HIV and hormonal contraception.. Lancet 
Infect Dis. 2015. http://dx.doi.org/10.1016/ S1473-3099(14)71076-X [Epub ahead of print]
6. Jain AK. Hormonal contraception and HIV acquisition risk: implications for individual users and 
public policies. Contraception. 2012; 86(6):645–52. [PubMed: 22541635] 
7. DMPA and HIV: why we need a trial. Contraception. 2014; 90(4):354–6. [PubMed: 25183263] 
8. Polis CB, Phillips SJ, Curtis KM, Westreich DJ, Steyn PS, Raymond E, et al. Hormonal 
contraceptive methods and risk of HIV acquisition in women: a systematic review of 
epidemiological evidence. Contraception. 2014; 90(4):360–90. [PubMed: 25183264] 
9. Ralph, LJ.; McCoy, SI.; Shiu, K.; Padian, NS. Lancet. Hormonal contraceptive use and women's 
risk of HIV acquisition: a meta-analysis of observational studies.. Infect Dis 2015, http://dx.doi.org/
10.1016/S1473-3099(14)71052-7 [Epub ahead of print]
10. Morrison CS, Chen PL, Kwok C, Baeten JM, Brown J, Crook AM, et al. Hormonal contraception 
and the risk of HIV acquisition: an individual participant data meta-analysis. PLoS Med. 2015; 
12(1):e1001778. http://dx.doi.org/10.1371/journal.pmed.1001778. [PubMed: 25612136] 
11. Polis CB, Westreich D, Balkus JE, Heffron R. Assessing the effect of hormonal contraception on 
HIV acquisition in observational data: challenges and recommended analytic approaches. AIDS. 
2013; 27(Suppl 1):S35–43. [PubMed: 24088682] 
12. Wall KM, Kilembe W, Nizam A, Vwalika C, Kautzman M, Chomba E, et al. Promotion of 
couples' voluntary HIV counselling and testing in Lusaka, Zambia by influence network leaders 
and agents. BMJ Open. 2012; 2(5)
13. Mark KE, Meinzen-Derr J, Stephenson R, Haworth A, Ahmed Y, Duncan D, et al. Contraception 
among HIV concordant and discordant couples in Zambia: a randomized controlled trial. J 
Womens Health (Larchmt). 2007; 16(8):1200–10. [PubMed: 17937573] 
14. Kempf MC, Allen S, Zulu I, Kancheya N, Stephenson R, Brill I, et al. Enrollment and retention of 
HIV discordant couples in Lusaka, Zambia. J Acquir Immune Defic Syndr. 2008; 47(1):116–25. 
[PubMed: 18030162] 
15. Boeras DI, Luisi N, Karita E, McKinney S, Sharkey T, Keeling M, et al. Indeterminate and 
discrepant rapid HIV test results in couples' HIV testing and counselling centres in Africa. J Int 
AIDS Soc. 2011; 14:14–8. http://dx.doi.org/10.1186/1758-2652-14-18. [PubMed: 21439074] 
16. Stephenson R, Barker J, Cramer R, Hall MA, Karita E, Chomba E, et al. The demographic profile 
of sero-discordant couples enrolled in clinical research in Rwanda and Zambia. AIDS Care. 2008; 
20(3):395–405. [PubMed: 18351489] 
17. Fideli US, Allen SA, Musonda R, Trask S, Hahn BH, Weiss H, et al. Virologic and immunologic 
determinants of heterosexual transmission of human immunodeficiency virus type 1 in Africa. 
AIDS Res Hum Retroviruses. 2001; 17(10):901–10. [PubMed: 11461676] 
18. Dionne-Odom J, Karita E, Kilembe W, Henderson F, Vwalika B, Bayingana R, et al. Syphilis 
treatment response among HIV-discordant couples in Zambia and Rwanda. Clin Infect Dis. 2013; 
56(12):1829–37. [PubMed: 23487377] 
19. Song W, He D, Brill I, Malhotra R, Mulenga J, Allen S, et al. Disparate associations of HLA class 
I markers with HIV-1 acquisition and control of viremia in an African population. PLoS One. 
2011; 6(8):e23469. [PubMed: 21858133] 
20. Trask SA, Derdeyn CA, Fideli U, Chen Y, Meleth S, Kasolo F, et al. Molecular epidemiology of 
human immunodeficiency virus type 1 transmission in a heterosexual cohort of discordant couples 
in Zambia. J Virol. 2002; 76(1):397–405. [PubMed: 11739704] 
Wall et al. Page 9













21. Campbell MS, Mullins JI, Hughes JP, Celum C, Wong KG, Raugi DN, et al. Viral linkage in 
HIV-1 seroconverters and their partners in an HIV-1 prevention clinical trial. PLoS One. 2011; 
6(3):e16986. [PubMed: 21399681] 
22. Haddad L, Wall KM, Vwalika B, Khu NH, Brill I, Kilembe W, et al. Contraceptive discontinuation 
and switching among couples receiving integrated HIV and family planning services in Lusaka, 
Zambia. AIDS. 2013; 27(Suppl 1):S93–103. [PubMed: 24088689] 
23. Wall KM, Haddad L, Vwalika B, Htee Khu N, Brill I, Kilembe W, et al. Unintended pregnancy 
among HIV positive couples receiving integrated HIV counseling, testing, and family planning 
services in Zambia. PLoS One. 2013; 8(9):e75353. [PubMed: 24098692] 
Wall et al. Page 10
































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Wall et al. Page 14
Table 3
Seroconversion rates among HIV-negative women in discordant relationships by method of contraception 
(N=1393 M+F– couples)
Number of seroconversions Couple-years of 
follow-up time
Seroincidence per 100 
couple-years
95% CI p (2-tailed)
*
Current contraceptive method 
used at follow-up visit
    Non-hormonal
^ 153 1902.3 8.0 6.8 9.4 ref
    OCPs 49 424.5 11.5 8.5 15.3 .114
    Injectables 41 392.3 10.5 7.5 14.2 .296
    Implant 9 122.9 7.3 3.3 13.9 .678
Total 252 2841.9 8.9 7.8 10.0
67 study intervals (accounting for 5.7 couple years) were missing contraceptive information.
^
Copper intrauterine device, none/condoms alone, permanent method.
*
From univariate Cox proportional hazards models.
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Table 4
Multivariate models of hormonal contraception use and time to HIV seroconversion (N=1393 M+F – couples)
Linked and unlinked infections Linked infections
aHR
* 95% CI p value (2-tailed) aHR
** 95% CI p value (2-tailed)
Current contraceptive method at follow-up visit
    Non-hormonal
^ ref ref
    Implant 1.08 0.53 2.20 .83 0.96 0.29 3.14 .947
    Injectables 1.19 0.81 1.73 .37 1.34 0.85 2.12 .204
    OCPs 1.29 0.92 1.80 .15 1.39 0.90 2.15 .140
aHR: adjusted hazard ratio.
*
Controlling for woman's age (per year increase), woman's literacy in Nyanja, genital ulceration of woman in past 3 months, genital inflammation 
of woman in the past 3 months, and time interval since enrollment (0-3 months versus > 3 months).
**
Controlling for * and baseline pregnancy, sperm present on a wet prep, couples' self-reported unprotected sex in the last 3 months, genital 
ulceration of man in past 3 months, genital inflammation of man in the past 3 months, and man's baseline log viral load (per log10 copies/mL 
increase).
^
Copper intrauterine device, none/condoms alone, permanent method.
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Table 5
Measures of unprotected sex by method of contraception (N=1393 M+F – couples)
Non-hormonal (IUD, none/
condoms alone, permanent 
method)
OCPs Injectable Implant p (2-tailed)
*
N intervals % N intervals % N intervals % N intervals %
Number of times sex with 
partner in project without 
a condom in the last 3 
months reported by 
woman (mean, S.D.)
2.47 8.78 2.87 9.10 2.42 7.96 1.25 4.88 ^&
Sex with study partner 
without a condom in past 
3 months reported by 
woman
^#&
    Yes 2644 29% 717 37% 640 34% 180 18%
    No 6321 71% 1198 63% 1221 66% 810 82%
Sperm present on wet 
prep in last 3 months
    Yes 570 7% 151 8% 113 6% 23 2%
    No 7836 93% 1774 92% 1805 94% 986 98%
*
chi-Square (or Fisher's exact) test for categorical variables; t-tests (unequal variance) for continuous variables.
^
p<.1 for tests of differences between OCP versus non-hormonal contraception distributions.
#
p<.001 for tests of differences between injectables versus non-hormonal contraception distributions.
&
p<.001 for tests of differences between implant versus non-hormonal contraception distributions.
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Table 6
Measures of protected and unprotected sex by pregnancy status (N=1393 M+F – couples)
Pregnant Post-partum (up to 6 months 
past delivery)
Not pregnant or post-
partum p (2-tailed)
*
N intervals % N intervals % N intervals %
Number of times sex with partner 
in project with a condom in the last 
3 months reported by woman 
(mean, S.D.)
16.67 17.09 8.77 12.05 19.59 20.09 ^#&
Number of times sex with partner 
in project without a condom in the 
last 3 months reported by woman 
(mean, S.D.)
6.10 14.42 1.53 6.59 2.25 8.05 ^#&
Sex with study partner with a 
condom in past 3 months reported 
by woman
^#&
    Yes 959 84% 322 63% 9257 87%
    No 180 16% 187 37% 1377 13%
Sex with study partner without a 
condom in past 3 months reported 
by woman
    Yes 593 52% 116 23% 3145 30% ^#&
    No 546 48% 393 77% 7490 70%
Sperm present on wet prep in last 3 
months
#
    Yes 95 9% 32 6% 690 7%
    No 966 91% 478 94% 9476 93%
*
chi-Square (or Fisher's exact) test for categorical variables; t tests (unequal variance) for continuous variables.
^
p<.01 for tests of differences between pregnant versus post-partum women.
#
p<.01 for tests of differences between pregnant versus not pregnant or post-partum women.
&
p<.01 for tests of differences between post-partum versus not pregnant or post-partum women.
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